Streefkerk

Amarna Therapeutics announces appointment of Dr Henk Streefkerk as new CEO

Retrieved on: 
Wednesday, June 7, 2023
Streefkerk, Medicine, Heart failure, Clinical trial, CMO, Doctor of Philosophy, Haemophilia B, Actelion, Medical director, Novartis, MD, Patient, Haemophilia, Therapy, Henk, Pharmaceutical industry, Organon

LEIDEN, Netherlands, June 7, 2023 /PRNewswire/ -- Amarna Therapeutics , a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Hemophilia B, today announces the appointment of Dr Henk Streefkerk as the Company's new Chief Executive Officer and Medical Director.

Key Points: 
  • LEIDEN, Netherlands, June 7, 2023 /PRNewswire/ -- Amarna Therapeutics , a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Hemophilia B, today announces the appointment of Dr Henk Streefkerk as the Company's new Chief Executive Officer and Medical Director.
  • Dr Streefkerk has a distinguished career as CMO of several biotechs, including PIQUR Therapeutics, Cellprotera and Rivia, and brings over a decade of experience working in big pharma including Novartis, Actelion and Organon.
  • "We are very pleased to introduce Henk Streefkerk as our new CEO.
  • Henk will be instrumental in leading Amarna towards the first in human clinical trial," said Thomas Eldered, Chairman of Amarna's supervisory board.

Amarna Therapeutics announces appointment of Dr Henk Streefkerk as new CEO

Retrieved on: 
Wednesday, June 7, 2023
Streefkerk, Medicine, Heart failure, Clinical trial, CMO, Doctor of Philosophy, Haemophilia B, Actelion, Medical director, Novartis, MD, Patient, Haemophilia, Therapy, Henk, Pharmaceutical industry, Organon

LEIDEN, Netherlands, June 7, 2023 /PRNewswire/ -- Amarna Therapeutics , a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Hemophilia B, today announces the appointment of Dr Henk Streefkerk as the Company's new Chief Executive Officer and Medical Director.

Key Points: 
  • LEIDEN, Netherlands, June 7, 2023 /PRNewswire/ -- Amarna Therapeutics , a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Hemophilia B, today announces the appointment of Dr Henk Streefkerk as the Company's new Chief Executive Officer and Medical Director.
  • Dr Streefkerk has a distinguished career as CMO of several biotechs, including PIQUR Therapeutics, Cellprotera and Rivia, and brings over a decade of experience working in big pharma including Novartis, Actelion and Organon.
  • "We are very pleased to introduce Henk Streefkerk as our new CEO.
  • Henk will be instrumental in leading Amarna towards the first in human clinical trial," said Thomas Eldered, Chairman of Amarna's supervisory board.